Valink Therapeutics vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage ADC biotech with ValiLinker site-specific conjugation technology; VLT-03 in Phase I for solid tumors and VLT-01 for brain metastases with $20.5M raised.
About
Valink Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for solid tumors using its proprietary ValiLinker technology — a site-specific conjugation platform that precisely attaches cytotoxic payloads to antibodies at defined positions, improving ADC stability, homogeneity, and therapeutic index compared to conventional random-conjugation approaches. Founded in 2020 and headquartered in Houston, Texas, Valink raised $20.5 million total including an $11.8 million Pre-Series A in October 2025 to advance its pipeline into clinical trials.\n\nValink's pipeline centers on VLT-03 (targeting solid tumors in Phase I trials) and VLT-01 (targeting solid tumors with brain metastases, addressing the significant unmet need in CNS-penetrating oncology therapeutics). The ValiLinker conjugation technology enables precise drug-to-antibody ratios and reduces off-target toxicity that has historically limited ADC tolerability — the platform differentiates Valink from earlier ADC developers by addressing the conjugation chemistry precision that drives therapeutic index improvements in this modality.\n\nIn 2025, Valink competes in the ADC space with Seagen (acquired by Pfizer), ImmunoGen (acquired by AbbVie), Daiichi Sankyo (partnered with AstraZeneca), and numerous clinical-stage biotech ADC developers. ADC development has become one of the most active areas in oncology after the commercial success of Enhertu (trastuzumab deruxtecan) demonstrated the potential of the modality. Valink's site-specific conjugation differentiation targets the technical limitations of first-generation ADCs that created toxicity issues. The 2025-2026 strategy focuses on Phase I dose escalation for VLT-03, building clinical proof-of-concept for the ValiLinker platform, and positioning for partnership or licensing discussions with large pharma.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.